Skip to main content

Advertisement

SpringerLink
Log in

Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The purpose of this study was to clarify the role of repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) in the management of recurrent peritoneal carcinomatosis of appendiceal origin.

Methods

Data were retrieved on 42 patients who underwent CRS + HIPEC; 29 repeat surgical procedures were performed in 13 patients.

Results

Complete cytoreduction was achieved in 12 of 13 patients by the second CRS. Repeat recurrence was detected in 11 patients, eight of whom underwent a third CRS. The peritoneal cancer index decreased from initial CRS to repeat CRS but was still higher than 18 in nine patients at the second CRS. Preoperative chemotherapy was given to three patients with early recurrence. Grade 3–5 morbidity and 90-day mortality were not significantly different between initial and repeat CRS. Five-year survival rates after first and second CRS were 75.5 and 67.7%, respectively. Complete cytoreduction at second CRS was a significant prognostic factor. Among patients with recurrence after the second CRS, patients who underwent a third CRS showed a better prognosis than those who did not.

Conclusions

Repeat CRS is oncologically beneficial, and the morbidity rate was as high as that of initial CRS. Complete cytoreduction was the key to successful long-term results. Although further recurrence was common, aggressive resection was useful, even in cases of diffuse recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69–76

    Article  PubMed  Google Scholar 

  2. Yan TD, Black D, Savady R et al (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14:484–492

    Article  PubMed  Google Scholar 

  3. Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456

    Article  PubMed  Google Scholar 

  4. Mogal H, Chouliaras K, Levine EA et al (2016) Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol 7:129–142

    PubMed  PubMed Central  Google Scholar 

  5. Esquivel J, Sugarbaker PH (2001) Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg 234:198–205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bijelic L, Yan TD, Sugarbaker PH (2008) Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol 98:295–299

    Article  PubMed  Google Scholar 

  7. Lord AC, Shihab O, Chandrakumaran K et al (2015) Recurrence and outcome after complete tumor removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumors. Eur J Surg Oncol 41:396–399

    Article  CAS  PubMed  Google Scholar 

  8. Smeenk RM, Verwaal VJ, Antonini N et al (2007) Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. Ann Surg Oncol 14:493–499

    Article  PubMed  Google Scholar 

  9. Delhorme JB, Honoré C, Benhaim L et al (2017) Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei. Eur J Surg Oncol 43:159–167

    Article  PubMed  Google Scholar 

  10. Sardi A, Jimenez WA, Nieroda C et al (2013) Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. Eur J Surg Oncol 39:1207–1213

    Article  CAS  PubMed  Google Scholar 

  11. Saxena A, Yan TD, Morris DL (2010) Critical assessment of preoperative and operative risk factors for complications after iterative peritonectomy procedures. Eur J Surg Oncol 36:309–314

    Article  CAS  PubMed  Google Scholar 

  12. Mohamed F, Chang D (2003) Sugarbaker PH (1995) Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination. J Surg Oncol 83:5–13

    Article  PubMed  Google Scholar 

  13. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Moran B, Baratti D, Yan TD et al (2008) Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasm with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 98:277–282

    Article  PubMed  Google Scholar 

  15. Ronnett BM, Yan H, Kurman RJ et al (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92:85–91

    Article  CAS  PubMed  Google Scholar 

  16. Chua TC, Quinn LE, Zhao J et al (2013) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastasis. J Surg Oncol 108:81–88

    Article  PubMed  Google Scholar 

  17. Chua TC, Liauw W, Morris DL (2012) Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome. Int J Colorectal Dis 27:381–389

    Article  PubMed  Google Scholar 

  18. Konstantinidis IT, Levine EA, Chouliaras K et al (2017) Interval between cytoreductions as a marker of tumor biology in selecting patients for repeatcytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. https://doi.org/10.1002/jso.24703

    PubMed  Google Scholar 

  19. Pietrantonio F, Maggi C, Fanetti G et al (2014) FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist 19:845–850

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bijelic L, Kumar AS, Stuart OA et al (2012) Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. Gastroenterol Res Pract 2012:163284. https://doi.org/10.1155/2012/163284

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgement

The authors thank Prof. Takayoshi Hirai, Fukui Prefectural University, for confirming that methods of statistical analysis were correct.

Funding

The authors have no organization that funded our research.

Author information

Authors and Affiliations

  1. Department of Surgery, Kishiwada City Hospital, 1001 Gakuhara-cho, Kishiwada, 596-8501, Osaka, Japan

    Toshiyuki Kitai & Kenya Yamanaka

Authors
  1. Toshiyuki Kitai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenya Yamanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiyuki Kitai.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest in association with this study.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kitai, T., Yamanaka, K. Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin. Int J Clin Oncol 23, 298–304 (2018). https://doi.org/10.1007/s10147-017-1217-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1217-8

Keywords

Search

Navigation